33 results about "RUNX1" patented technology

The invention discloses a kit for predicting the prognosis risk of lung squamous cell carcinoma and its application, and relates to the technical fields of genetic engineering and oncology. The kit can detect the sequence information of the target region, and the target region is selected from the regions in Table 1 1-127, which are located in the specific regions of ARID1A, SLC43A2, ANKS1A, CHD2, RPTOR, OR7A5 and RUNX1 genes. By detecting the sequence information of the target regions, it can effectively and quickly predict the prognosis risk of lung squamous cell carcinoma patients. These targets Compared with other clinical markers, regional mutations have higher specificity, and the detection is convenient and quick.

The invention discloses a method and primers for detecting a fifth exon mutation site of a RUNX1 gene. The method and the primers comprise a forward primer, a reverse primer and a pair of sequencing primers for amplifying the fifth exon mutation site of the RUNX1 gene. The method combines a Touch-down PCR amplification and a Sanger sequencing method, can rapidly detect mutation conditions of the fifth exon mutation site of the RUNX1 gene in an acute myeloid leukemia patient body.

The invention provides a kit for joint detection of acute myeloid leukemia, which includes special adapters for DNA library construction and specific compound primers for detecting gene rearrangement and gene whole exon mutation and composite primers for library amplification. The special linker is 8 dimers composed of linker primer 1 and 8 different i5 end primers respectively; the types of gene rearrangement and gene whole exon mutation are CBFB rearrangement, RUNX1 rearrangement, MLL rearrangement, RARA rearrangement, MECOM rearrangement, whole exon mutation of TP53 gene; library amplification compound primers have different i7 ends. The kit provided by the invention can detect multiple common molecular genetic variations of acute myeloid leukemia at one time, and has simple operation, short time and high detection efficiency.

This invention relates to compounds that bind to wild-type CBFβ and inhibit CBFβ binding to RUNX proteins. The potent compounds of the invention inhibit this protein-protein interaction at low micromolar concentrations, using allosteric mechanism to achieve inhibition, displace wild-type CBFβ from RUNX1 in cells, change occupancy of RUNX1 on target genes, and alter gene expression of RUNX1 target genes. These inhibitors show clear biological effects consistent with on-target RUNX protein activity. Pharmaceutical compositions containing a compound of the invention and a pharmaceutically acceptable carrier represent a separate embodiment of the invention. Another embodiment of the invention are methods of treating a RUNX-signaling-dependent cancer that expresses wild-type CBFβ in a subject in need thereof by administering to the subject a therapeutically effective amount of a compound of the invention. In one embodiment, the cancer is selected from the group consisting of a RUNX-signaling-dependent leukemia that expresses wild-type CBFβ, lung cancer, bladder cancer, ovarian cancer, uterine cancer, endometrial cancer, breast cancer, liver cancer, pancreatic cancer, stomach cancer, cervical cancer, lymphoma, leukemia, acute myeloid leukemia, acute lymphocytic leukemia, salivary gland cancer, bone cancer, brain cancer, colon cancer, rectal cancer, colorectal cancer, kidney cancer, skin cancer, melanoma, squamous cell carcinoma of the tongue, pleomorphic adenoma, hepatocellular carcinoma, pancreatic cancer, squamous cell carcinoma, and / or adenocarcinoma. In another embodiment, the compounds of the invention can be used to treat a leukemia, lung cancer, ovarian cancer, and / or breast cancer.